# A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

> **NCT06146660** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 600 (estimated)

## Conditions studied

- Obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Mavacamten

## Key facts

- **NCT ID:** NCT06146660
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-24
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06146660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06146660, "A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06146660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*